皮肤自发荧光可预测普通人群2型糖尿病、心血管疾病与死亡风险
基于荷兰Lifelines队列72,880名基线无糖尿病和心血管疾病的参与者,随访中位4年后发现,皮肤自发荧光升高者发生2型糖尿病、心血管疾病和死亡的风险增加,且独立于代谢综合征、血糖和HbA1c等传统危险因素,提示其可作为无创筛查工具。
要点
- 皮肤自发荧光可独立于血糖和代谢综合征预测2型糖尿病风险
- 皮肤自发荧光升高与心血管事件及全因死亡风险增加相关
- 该无创测量或可用于普通人群未来代谢与心血管风险的筛查
核心结论
- 皮肤自发荧光测量对筛查普通人群未来2型糖尿病、心血管疾病和死亡风险具有临床价值,且独立于血糖指标和代谢综合征。
研究设计与样本
- 前瞻性分析,纳入荷兰Lifelines队列研究中72,880名2007至2013年间接受基线调查、基线皮肤自发荧光值有效且无已知糖尿病或心血管疾病的参与者。
主要发现
- 中位随访4年(范围0.5-10年)后,1056人(1.4%)发生2型糖尿病,1258人(1.7%)诊断心血管疾病,928人(1.3%)死亡。
- 发生2型糖尿病和/或心血管疾病者及死亡者基线皮肤自发荧光升高(均p < 0.001),相比存活且未患这两种疾病者。
- 皮肤自发荧光可预测2型糖尿病、心血管疾病和死亡的发生,独立于代谢综合征、血糖和HbA1c等传统危险因素。
关键数值与推荐
- 2型糖尿病诊断依据自我报告或随访时空腹血糖≥7.0 mmol/l或HbA1c≥48 mmol/mol(≥6.5%)。
- 心血管疾病诊断依据自我报告,包括心肌梗死、冠脉介入、脑血管意外、短暂性脑缺血发作、间歇性跛行或血管手术。
- 死亡信息通过市政个人记录数据库确认。
临床怎么用
- 在普通人群筛查中,可考虑用无创皮肤自发荧光测量辅助识别未来2型糖尿病、心血管疾病和死亡高风险个体,作为传统危险因素之外的补充。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Earlier studies have shown that skin autofluorescence measured with an AGE reader estimates the accumulation of AGEs in the skin, which increases with ageing and is associated with the metabolic syndrome and type 2 diabetes. In the present study, we examined whether the measurement of skin autofluorescence can predict 4 year risk of incident type 2 diabetes, cardiovascular disease (CVD) and mortality in the general population. METHODS: For this prospective analysis, we included 72,880 participants of the Dutch Lifelines Cohort Study, who underwent baseline investigations between 2007 and 2013, had validated baseline skin autofluorescence values available and were not known to have diabetes or CVD. Individuals were diagnosed with incident type 2 diabetes by self-report or by a fasting blood glucose ≥7.0 mmol/l or HbA1c ≥48 mmol/mol (≥6.5%) at follow-up. Participants were diagnosed as having incident CVD (myocardial infarction, coronary interventions, cerebrovascular accident, transient ischaemic attack, intermittent claudication or vascular surgery) by self-report. Mortality was ascertained using the Municipal Personal Records Database. RESULTS: After a median follow-up of 4 years (range 0.5-10 years), 1056 participants (1.4%) had developed type 2 diabetes, 1258 individuals (1.7%) were diagnosed with CVD, while 928 (1.3%) had died. Baseline skin autofluorescence was elevated in participants with incident type 2 diabetes and/or CVD and in those who had died (all p < 0.001), compared with individuals who survived and remained free of the two diseases. Skin autofluorescence predicted the development of type 2 diabetes, CVD and mortality, independent of several traditional risk factors, such as the metabolic syndrome, glucose and HbA1c. CONCLUSIONS/INTERPRETATION: The non-invasive skin autofluorescence measurement is of clinical value for screening for future risk of type 2 diabetes, CVD and mortality, independent of glycaemic measures and the metabolic syndrome.
引用
- van Waateringe RP, Fokkens BT, Slagter SN, et al. Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population. Diabetologia. 2018. PMID: 30460578. doi:10.1007/s00125-018-4769-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。